

# A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis

NCT07013201

---

Status	RECRUITING
Phase	Phase 2
Sponsor	LEO Pharma
Enrollment	135 participants

## Key Eligibility Criteria

---

### Inclusion (12)

- Signed and dated informed consent has been obtained prior to any protocol-related procedures.
  - Age 18 years or above at the time of informed consent signing.
  - Participant is able to comply with clinic visits and trial requirements and procedures, as assessed by the investigator.
  - Diagnosis of PPP in accordance with the consensus diagnostic criteria established by European Rare and Severe Psoriasis Expert Network: primary, persistent (>3 months duration), sterile, macroscopically visible pustules on the palms and/or soles, with or without plaque psoriasis elsewhere on the body.
  - Confirmed PPP by central evaluation of photographs taken at screening.
- ... and 7 more (see full listing online)

### Exclusion (34)

- Presence or known history of drug-induced PPP (e.g., a new onset of PPP or an exacerbation of PPP from beta blockers, calcium channel blockers, lithium, or biologic therapy including infliximab, adalimumab, or etanercept).
  - Presence of acrodermatitis continua of Hallopeau.
  - Active dermatologic condition that could confound the diagnosis of PPP or interfere with assessment of the IMP, as assessed by the investigator.
  - Clinically significant infection on the palms or soles.
  - Concurrent plaque psoriasis covering >5% of body surface area.
- ... and 29 more (see full listing online)

## Locations (36 total)

---

LEO Pharma Investigational Site, Fountain Valley, California, United States  
LEO Pharma Investigational Site, Douglasville, Georgia, United States  
LEO Pharma Investigational Site, West Bloomfield, Michigan, United States  
... and 33 more locations